• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Individualized Medicine in Ovarian Cancer: Are We There Yet?

作者信息

Westin Shannon N, Coleman Robert L

机构信息

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030.

出版信息

Gynecol Oncol. 2017 Feb;144(2):229-231. doi: 10.1016/j.ygyno.2017.01.006.

DOI:10.1016/j.ygyno.2017.01.006
PMID:28089051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5881923/
Abstract
摘要

相似文献

1
Individualized Medicine in Ovarian Cancer: Are We There Yet?卵巢癌的个体化医疗：我们做到了吗？
Gynecol Oncol. 2017 Feb;144(2):229-231. doi: 10.1016/j.ygyno.2017.01.006.
2
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.第五届卵巢癌共识会议：个体化治疗与患者因素。
Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.
3
Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.开发用于卵巢癌个体化治疗的临床分子检测：精准医学信息学与临床及卫生经济学维度的相互作用。
AMIA Annu Symp Proc. 2018 Dec 5;2018:1093-1102. eCollection 2018.
4
A step towards the ambition of precision oncology in recurrent ovarian cancer.迈向复发性卵巢癌精准肿瘤学目标的一步。
J Gynecol Oncol. 2022 Jul;33(4):e64. doi: 10.3802/jgo.2022.33.e64. Epub 2022 Jun 14.
5
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.上皮性卵巢癌：精准医学时代的治疗进展。
CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.
6
From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.从卵巢癌的靶向治疗到卵巢癌的个体化治疗。
Expert Opin Investig Drugs. 2011 May;20(5):591-4. doi: 10.1517/13543784.2011.571202.
7
The rise of genomic profiling in ovarian cancer.卵巢癌中基因组分析的兴起。
Expert Rev Mol Diagn. 2016 Dec;16(12):1337-1351. doi: 10.1080/14737159.2016.1259069.
8
Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine.新诊断晚期上皮性卵巢癌的全身治疗：从化疗到精准医学。
Crit Rev Oncol Hematol. 2021 Feb;158:103209. doi: 10.1016/j.critrevonc.2020.103209. Epub 2020 Dec 31.
9
Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine.卵巢上皮性癌差异表达基因的数据挖掘：精准医学的启示。
Curr Top Med Chem. 2021 Oct 5;21(14):1285-1300. doi: 10.2174/1568026621666210708093649.
10
Personalising Treatment for High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌的个体化治疗。
Clin Oncol (R Coll Radiol). 2018 Aug;30(8):515-524. doi: 10.1016/j.clon.2018.05.008. Epub 2018 Jun 19.

本文引用的文献

1
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).一项舒尼替尼治疗持续性或复发性透明细胞卵巢癌的 II 期评估：NRG 肿瘤学/妇科肿瘤学组研究（GOG-254）。
Gynecol Oncol. 2018 Aug;150(2):247-252. doi: 10.1016/j.ygyno.2018.05.029. Epub 2018 Jun 18.
2
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).为晚期 I 型上皮性卵巢癌（EOC）患者进行基因匹配治疗。
Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.
3
New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy.肿瘤相关巨噬细胞促进肿瘤进展的新机制：肿瘤免疫治疗的最新研究进展和潜在靶点。
J Immunol Res. 2016;2016:9720912. doi: 10.1155/2016/9720912. Epub 2016 Nov 16.
4
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.尼拉帕利维持治疗铂敏感复发性卵巢癌。
N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
5
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
6
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment.缺氧诱导因子依赖性信号通路在三阴性乳腺癌细胞和间充质干细胞之间的相互作用促进了巨噬细胞的募集。
Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2120-9. doi: 10.1073/pnas.1406655111. Epub 2014 May 5.
7
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.贝伐珠单抗联合化疗治疗铂耐药复发性卵巢癌：AURELIA 开放性随机 III 期试验。
J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.
8
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.卵巢浆液性交界性肿瘤中 KRAS（而非 BRAF）突变与复发性低级别浆液性癌相关。
J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.
9
Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells.缺氧诱导因子介导乳腺癌细胞中 RhoA-ROCK1 的表达和信号传导的协调作用。
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):E384-93. doi: 10.1073/pnas.1321510111. Epub 2013 Dec 9.
10
Mechanisms of resistance to therapies targeting BRCA-mutant cancers.针对 BRCA 突变型癌症的治疗的耐药机制。
Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7.